Nutra Pharma partners with EuroAmerican IP to distribute Nyloxin for sale to government agencies.
Nutra Pharma Corp., a biotechnology company marketing Nyloxin and Pet Pain-Away in the over-the-counter (OTC) pain management market, has partnered with EuroAmerican IP, LLC to distribute the OTC Nyloxin Topical Gel, through the Federal Supply Schedule (FSS).
The successful addition to FSS will make the product available for purchase through the U.S. General Services Administration’s GSA Advantage website at www.gsaadvantage.gov.
“With the nation focused on the treatment of chronic pain and the reduction of opiate use, especially for veterans, Nyloxin should go a long way to effectively managing chronic pain symptoms for many of our wounded warriors and reducing their use of opiate drugs,” stated Rik J Deitsch, CEO of Nutra Pharma. “By partnering with EuroAmerican, we expect to be able to effectively distribute our products directly to various agencies and health departments.”
He added that the plan is to begin actively marketing Nyloxin Topical Gel through the GSA Advantage to governmental agencies, including the Department of Veterans Affairs.
The U.S. Department of Defense has been reporting an increase in the use and abuse of prescription medications; particularly opiates. In October, the Federal government declared the opiate epidemic a national public health emergency. But prescription drugs are not the only issue.
The most common and seemingly harmless way to treat pain is with non-steroidal, anti-inflammatory drugs (NSAIDS). But these have risks as well. Overuse can cause nausea, vomiting, diarrhea, heartburn, ulcers, and internal bleeding. In severe cases chest pain, heart failure, kidney dysfunction, and life-threatening allergic reactions can occur.
Ibuprofen, also an NSAID, has been of particular concern in the military. The terms “Ranger Candy” and “Military Candy” refer to the service men and women who are said to use 800mg doses of Ibuprofen to control their pain.
But when taking anti-inflammatory Ibuprofen in high doses for chronic pain, there is potential for critical health risks; abuse can lead to serious stomach problems, internal bleeding, and even kidney failure. There are significantly greater health risks when abuse of this drug is combined with alcohol intake.
Nyloxin is a non-narcotic, and non-addictive Homeopathic pain reliever clinically proven to treat moderate to severe chronic pain while not impairing cognitive function. It offers several benefits as pain relievers and anti-inflammatory agents.
With increasing concern about consumers using opioid and acetaminophen-based pain relievers, Nyloxin offers an alternative that does not rely on opiates or non-steroidal anti-inflammatory drugs, otherwise known as NSAIDs, for their pain relieving effects. Nyloxin has a well-defined safety profile. Since the early 1930s, the active pharmaceutical ingredient (API), Asian cobra venom, has been studied in more than 46 human clinical studies.
EuroAmerican IP, LLC, a small, woman-owned business, functions as a medical supply distributor by providing various industries and government facilities with a line of products within the medical, health, and outdoor arenas.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), and Pain.
(Source: Nutra Pharma Corp.)